EGFR has been identified as a predictive biomarker for chemotherapy or radiation/chemotherapy benefits and survival in oropharyngeal cancer and for targeted therapy benefit in HNSCC (20, 21). The gene discussed is EGFR; the disease is oropharynx cancer.